Compare M&T Bank Corporation (MTB) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
M&T Bank Corporation vs Recursion Pharmaceuticals Inc — how do they compare? M&T Bank Corporation trades at $237.67 (market cap $34.43B), while Recursion Pharmaceuticals Inc trades at $3.23 (market cap $1.86B). The key difference: M&T Bank Corporation is far larger — about 18.5× Recursion Pharmaceuticals Inc's market cap, and M&T Bank Corporation pays a 2.52% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| MTB | RXRX | |
|---|---|---|
Market Cap | $34.43B | $1.86B |
Sector | Financials | Health |
52-Week High | $254.09 | $6.79 |
52-Week Low | $178.63 | $2.84 |
Dividend Yield | 2.52% | — |
Enterprise Value | — | $1.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MTB trades at $238.44, down 0.58% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported three consecutive quarterly EPS beats, with Q2 2026 EPS of $5.35 surpassing the $4.66 estimate. Revenue for 2025 reached $9.63 billion, with a net income margin of 30.85%. Recent news highlights participation in the Barclays Global Financial Services Conference and a declared quarterly dividend of $1.50 per share.
The outlook for MTB is supported by strong earnings performance and a consensus price target of $261.62, implying about 10% upside. However, risks include a negative net cash flow of -$2.01 billion in 2025 and elevated debt levels, with a debt-to-asset ratio of 6.09. Investor sentiment is mixed, with 31% of analysts rating it a buy but 60% recommending hold, reflecting caution amid macroeconomic pressures.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
